Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282237 | 0.82 | TRPV6 (0.52) | ENPP2MRGPRX4CA6CA14 | |
| SCHEMBL2399166 | 0.81 | TSHR (0.50) | ENPP2CA2CA9 | |
| SCHEMBL2399007 | 0.80 | TRPV6 (0.52) | ENPP2MRGPRX4 | |
| SCHEMBL2398396 | 0.79 | ENPP2 (0.47) | ENPP2MAOBMRGPRX4CA2 | |
| SCHEMBL14503425 | 0.77 | ORAI1 (0.59) | ENPP2MRGPRX4 | |
| SCHEMBL1138626 | 0.75 | ENPP2 (0.53) | ENPP2CA12CA2CA3CA6 | |
| SCHEMBL2405727 | 0.75 | ENPP2 (0.73) | ENPP2LOXL2CA12CA2CA3 | |
| SCHEMBL2407138 | 0.74 | ENPP2 (0.35) | ENPP2MAOB | |
| SCHEMBL25282956 | 0.74 | MC4R (0.44) | — | |
| SCHEMBL6668868 | 0.73 | MRGPRX4 (0.55) | MAOBMRGPRX4FFAR1FFAR4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | claimed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | claimed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | claimed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | claimed |
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | ENPP2 3251/4885MAOB 627/4885MRGPRX4 2377/4885 |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | ENPP2 3574/4885MAOB 1138/4885MRGPRX4 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.